Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Accured Expenses (2016 - 2018)

Historic Change in Accured Expenses for Ani Pharmaceuticals (ANIP) over the last 9 years, with Q3 2018 value amounting to $1.0 million.

  • Ani Pharmaceuticals' Change in Accured Expenses fell 4314.27% to $1.0 million in Q3 2018 from the same period last year, while for Sep 2018 it was $174000.0, marking a year-over-year increase of 7400.0%. This contributed to the annual value of $644000.0 for FY2017, which is 3148.94% down from last year.
  • According to the latest figures from Q3 2018, Ani Pharmaceuticals' Change in Accured Expenses is $1.0 million, which was down 4314.27% from -$749000.0 recorded in Q2 2018.
  • Ani Pharmaceuticals' 5-year Change in Accured Expenses high stood at $1.8 million for Q3 2017, and its period low was -$1.9 million during Q4 2015.
  • In the last 5 years, Ani Pharmaceuticals' Change in Accured Expenses had a median value of $143000.0 in 2014 and averaged $171473.7.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 52307.69% in 2015, then skyrocketed by 4512500.0% in 2017.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Change in Accured Expenses stood at -$630000.0 in 2014, then crashed by 198.57% to -$1.9 million in 2015, then grew by 8.88% to -$1.7 million in 2016, then soared by 31.74% to -$1.2 million in 2017, then skyrocketed by 187.52% to $1.0 million in 2018.
  • Its Change in Accured Expenses was $1.0 million in Q3 2018, compared to -$749000.0 in Q2 2018 and $1.1 million in Q1 2018.